semaglutide lowers risk of heart issues regardless of weight loss 2.4 mg delivered a statistically significant 20% reduction in major adverse cardiovascular events – REGENHEALTHSOLUTIONS (RHS) A 2025 Lancet analysis of

according to Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data, 23% of reports included nausea, a reminder that gastrointestinal upset is a common, clinically meaningful event

Faubion is just finishing up a study of 160 pre-, peri-, and postmenopausal women on GLP-1ssome of whom are also on MHTand hopes to have the results available by the fall

Estrogen Receptor beta as a Therapeutic Target in Breast Cancer Stem Cells

Researchers and scientists are continuously seeking synergistic approaches to complex biological systems

Bioavailability data in humans is scarce, though animal studies suggest oral dosing retains gastrointestinal healing effects 4

In most cases, patients with a BMI below 27 do not qualify for GLP-1 medications prescribed specifically for weight management